354 related articles for article (PubMed ID: 19193910)
1. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.
Silverberg SJ; Lewiecki EM; Mosekilde L; Peacock M; Rubin MR
J Clin Endocrinol Metab; 2009 Feb; 94(2):351-65. PubMed ID: 19193910
[TBL] [Abstract][Full Text] [Related]
2. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype.
Lowe H; McMahon DJ; Rubin MR; Bilezikian JP; Silverberg SJ
J Clin Endocrinol Metab; 2007 Aug; 92(8):3001-5. PubMed ID: 17536001
[TBL] [Abstract][Full Text] [Related]
3. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.
Khan A; Grey A; Shoback D
J Clin Endocrinol Metab; 2009 Feb; 94(2):373-81. PubMed ID: 19193912
[TBL] [Abstract][Full Text] [Related]
4. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.
Silverberg SJ; Clarke BL; Peacock M; Bandeira F; Boutroy S; Cusano NE; Dempster D; Lewiecki EM; Liu JM; Minisola S; Rejnmark L; Silva BC; Walker MD; Bilezikian JP
J Clin Endocrinol Metab; 2014 Oct; 99(10):3580-94. PubMed ID: 25162667
[TBL] [Abstract][Full Text] [Related]
5. Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism.
Koumakis E; Souberbielle JC; Payet J; Sarfati E; Borderie D; Kahan A; Cormier C
Osteoporos Int; 2014 Jul; 25(7):1963-8. PubMed ID: 24676846
[TBL] [Abstract][Full Text] [Related]
6. Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism.
Marcocci C; Bollerslev J; Khan AA; Shoback DM
J Clin Endocrinol Metab; 2014 Oct; 99(10):3607-18. PubMed ID: 25162668
[TBL] [Abstract][Full Text] [Related]
7. An overview of normocalcemic primary hyperparathyroidism.
Pawlowska M; Cusano NE
Curr Opin Endocrinol Diabetes Obes; 2015 Dec; 22(6):413-21. PubMed ID: 26512768
[TBL] [Abstract][Full Text] [Related]
8. Clinical, Biochemical, and Radiological Profile of Normocalcemic Primary Hyperparathyroidism.
Palermo A; Naciu AM; Tabacco G; Falcone S; Santonati A; Maggi D; D'Onofrio L; Briganti SI; Castellitto D; Casini A; Pedone C; Lelli D; Fabbri A; Bilezikian JP; Napoli N; Pozzilli P; Manfrini S; Cesareo R
J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32271382
[TBL] [Abstract][Full Text] [Related]
9. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.
Rubin MR; Bilezikian JP; McMahon DJ; Jacobs T; Shane E; Siris E; Udesky J; Silverberg SJ
J Clin Endocrinol Metab; 2008 Sep; 93(9):3462-70. PubMed ID: 18544625
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism.
Koumakis E; Souberbielle JC; Sarfati E; Meunier M; Maury E; Gallimard E; Borderie D; Kahan A; Cormier C
J Clin Endocrinol Metab; 2013 Aug; 98(8):3213-20. PubMed ID: 23783096
[TBL] [Abstract][Full Text] [Related]
11. Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism.
Beysel S; Caliskan M; Kizilgul M; Apaydin M; Kan S; Ozbek M; Cakal E
BMC Cardiovasc Disord; 2019 May; 19(1):106. PubMed ID: 31068134
[TBL] [Abstract][Full Text] [Related]
12. Current opinions on nephrolithiasis associated with primary hyperparathyroidism.
Cong X; Shen L; Gu X
Urolithiasis; 2018 Oct; 46(5):453-457. PubMed ID: 29350243
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.
Eastell R; Arnold A; Brandi ML; Brown EM; D'Amour P; Hanley DA; Rao DS; Rubin MR; Goltzman D; Silverberg SJ; Marx SJ; Peacock M; Mosekilde L; Bouillon R; Lewiecki EM
J Clin Endocrinol Metab; 2009 Feb; 94(2):340-50. PubMed ID: 19193909
[TBL] [Abstract][Full Text] [Related]
14. Hypomagnesuria is Associated With Nephrolithiasis in Patients With Asymptomatic Primary Hyperparathyroidism.
Saponaro F; Marcocci C; Apicella M; Mazoni L; Borsari S; Pardi E; Di Giulio M; Carlucci F; Scalese M; Bilezikian JP; Cetani F
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32369583
[TBL] [Abstract][Full Text] [Related]
15. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
[TBL] [Abstract][Full Text] [Related]
16. Impact of parathyroidectomy on cardiovascular risk in primary hyperparathyroidism: A narrative review.
Frey S; Mirallié É; Cariou B; Blanchard C
Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):981-996. PubMed ID: 33612382
[TBL] [Abstract][Full Text] [Related]
17. Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism.
Nakaoka D; Sugimoto T; Kobayashi T; Yamaguchi T; Kobayashi A; Chihara K
J Clin Endocrinol Metab; 2000 May; 85(5):1901-7. PubMed ID: 10843172
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and Skeletal Outcomes of Parathyroidectomy for Normocalcemic (Incipient) Primary Hyperparathyroidism.
Sho S; Kuo EJ; Chen AC; Li N; Yeh MW; Livhits MJ
Ann Surg Oncol; 2019 Feb; 26(2):539-546. PubMed ID: 30406488
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density improvement after successful parathyroidectomy in pre- and postmenopausal women with primary hyperparathyroidism: a prospective study.
Lumachi F; Camozzi V; Ermani M; DE Lotto F; Luisetto G
Ann N Y Acad Sci; 2007 Nov; 1117():357-61. PubMed ID: 17646261
[TBL] [Abstract][Full Text] [Related]
20. Normocalcemic Hyperparathyroidism.
Corbetta S
Front Horm Res; 2019; 51():23-39. PubMed ID: 30641527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
